Evolving Strategies in the Diagnosis and Treatment of Muscle-Invasive Bladder Cancer – Enduring Webcast

Description

Program Description

---

This enduring webcast will provide up-to-date information on diagnosis and therapeutic options for metastatic muscle-invasive bladder cancer (MIBC) and adverse events management. The activity will focus on:

• Clinical Spectrum of MIBC – Clinical spectrum of bladder cancer can be divided into 3 categories that differ in prognosis, management, and therapeutic aims
• Mutational burden is higher in MIBC – Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, and STAG2, as well as genes involved in chromatin modification
• Diagnosis – Urine and CtDNA based diagnosis of MIBC
• Treatment Options for MIBC
  • Neoadjuvant Chemotherapy for MIBC – methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), and a combination of gemcitabine and cisplatin
  • Adjuvant Therapy for MIBC – Nivolumab, radiation therapy
  • Ongoing Immunotherapy Clinical Trials for MIBC
  • Neoadjuvant Therapy – Single-agent ICI, Combination ICIs
• HER2 – ADCs in Bladder Cancer
  • Trastuzumab emtansine (TDM-1)
  • Disitamab vedotin
• Treatment-Related Adverse Events (TRAE) – 2020 Updates to the NCCN Guidelines – Management of Immunotherapy-Related Toxicities
  • Gastrointestinal adverse events: Diarrhea/Colitis
  • Management of moderate (Grade 2) diarrhea/colitis
  • Cardiovascular adverse events
  • Management of cardiovascular adverse events

Intended Audience

---

US medical oncologists, ex-US medical oncologists, urologists, advanced practice providers (physician assistants and nurse practitioners), and nurses who manage patients with muscle-invasive bladder cancer (MIBC).

Commercial Supporter

---

Supported by an educational grant from Pfizer, Inc. and Astellas Pharma US, Inc.